“Some recent iterations. Last month, Eli Lilly announced…” — The Prof G Pod with Scott Galloway at 5:01
“Some recent iterations. Last month, Eli Lilly announced that its phase 3 trial for retitrutide, a triple agonist dubbed Godzilla that activates GLP-1, GIP, and glucagon receptors, appears to exceed the performance of other weight loss medications. On average, patients on ZepBound or Wegovi lose between 14% and 20% of…”
0:00
15:41